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The BCR-ABL tyrosine kinase produced by the t(9;
22)(q34;q11) translocation, also known as the Phila-
delphia chromosome, is the initiating event in
chronic myeloid leukemia (CML) and Ph acute lym-
phoblastic leukemia (ALL). Targeting of BCR-ABL with
tyrosine kinase inhibitors (TKIs) has resulted in rapid
clinical responses in the vast majority of patients with
CML and Philadelphia chromosome ALL. However,
long-term use of TKIs occasionally results in emer-
gence of therapy resistance, in part through the se-
lection of clones with mutations in the BCR-ABL ki-
nase domain. We present here an overview of the
current practice in monitoring for such mutations,
including the methods used, the clinical and labora-
tory criteria for triggering mutational analysis, and
the guidelines for reporting BCR-ABL mutations. We
also present a proposal for a public database for cor-
relating mutational status with in vitro and in vivo
responses to different TKIs to aid in the interpreta-
tion of mutation studies. (J Mol Diagn 2009, 11:4–11;
DOI: 10.2353/jmoldx.2009.080095)
Treatment of chronic myeloid leukemia (CML) and Phila-
delphia chromosome (Ph) acute lymphoblastic leuke-
mia (ALL) represents a model for targeted cancer ther-
apy, with the demonstration that ATP-competitive kinase
inhibitors that block BCR-ABL kinase activity, particularly
imatinib mesylate (Gleevec), can induce durable re-
sponses in the vast majority of patients. However, the
emergence of resistant leukemia clones bearing muta-
tions in the BCR-ABL kinase domain (KD) represent a
major mechanism of disease recurrence that can be
treated by changing therapy, often to another tyrosine
kinase inhibitor (TKI) that differs with respect to pharma-
cokinetics and kinase inhibitory properties.
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Although differences still exist between laboratories
in the methodology and timing of molecular monitoring in
CML, they are becoming increasingly standardized. In
most centers, reverse transcription quantitative polymer-
ase chain reaction (RQ-PCR) assessment for the BCR-
ABL transcript, a fusion of the BCR and ABL1 genes, has
become the standard monitoring assay for residual dis-
ease with testing done every 3 to 6 months over the
course of disease. The treatments and the algorithms for
monitoring responses in Ph ALL are more variable, with
more intensive monitoring by both multiparameter flow
cytometry and RQ-PCR commonly used in the first year
after treatment has begun.
To further standardization efforts, we present here guide-
lines for BCR-ABL mutational analysis including consider-
ations of triggers for analysis, assay performance, and re-
porting, and include a summary of current practice in
clinical laboratories in the United States and Canada. Al-
though we do not intend to fully define standards of practice
in this article, the suggested guidelines contribute to this
effort and point out areas that need further development.
What Is the Clinical Rationale for Detection of
BCR-ABL Point Mutations in CML and Ph ALL?
In CML, most data on the frequency of BCR-ABL KD
mutations and their clinical significance has been gener-
ated from patients with cytogenetic or hematological re-
sistance or relapse. Among patients with chronic phase
CML who develop (secondary) resistance to imatinib,
30% to 50% will have one or more BCR-ABL KD muta-
tions detectable by direct DNA sequencing,1,2 whereas
mutation frequencies are higher in those with accelerated
or blast phases of disease, especially in lymphoid blast
phases.3 The absence of a BCR-ABL KD mutation does
not exclude acquired drug resistance, since other less
common mechanisms of resistance include BCR-ABL
gene amplification, BCR-ABL overexpression, alterations
in drug efflux kinetics, upregulation of other kinase path-
ways, and rare BCR-ABL mutations outside of the KD.
Causes of therapy resistance unrelated to kinase activity
are typically due to additional oncogenic activation or
loss of tumor suppressor function, often manifested by
additional karyotypic changes.
The prognostic significance of finding any BCR-ABL
KD mutation, or any specific mutation such as T315I, is
complex and is described in more detail below. Some
studies, for example, have shown no differences in pro-
gression-free survival in TKI-resistant CML with or without
BCR-ABL KD mutation.1,3–5 However, in those patients
with imatinib resistance due to KD mutations, use of more
potent kinase inhibitors, including dasatinib, nilotinib, and
bosutinib can often overcome resistance in the subset of
patients in which the specific acquired BCR-ABL KD
mutation observed does not cause resistance to the al-
ternate drug.6,7
As compared with CML, BCR-ABL KD mutations occur
much more frequently (80% to 90% of cases) at the time
of relapse in Ph ALL8,9 in those patients who have been
treated with TKIs as initial or maintenance therapy. Lym-
phoid blast transformation of CML is also associated with
a similar high rate of new BCR-ABL KD mutations.10
Using more sensitive detection methods, low-levels of a
point mutation clone occasionally have even been de-
tected in Ph ALL before exposure to TKIs, suggesting that
resistant clones may precede TKI selection in some cases
of ALL.8 The detection of a BCR-ABL KD mutation at re-
lapse in Ph ALL usually is followed by a switch to a new
TKI along with salvage polychemotherapy.
When Should BCR-ABL Mutational Analysis Be
Performed?
Since BCR-ABL KD mutations in CML and Ph ALL can
occasionally be found in patients without clinical evi-
dence of resistant disease,11,12 the question remains
when to test for mutations and by what method. An inter-
national consensus group was convened to develop
guidelines for use of BCR-ABL transcript monitoring and
mutation testing in CML, formalizing its recommendations
at a meeting at the National Institutes Health in 2005 and
subsequently in a publication in 2006.13 Following these
recommendations, BCR-ABL KD mutation screening in
chronic phase CML is only recommended for those pa-
tients with inadequate initial response to TKIs or those
with evidence of loss of response. Mutation screening is
also recommended at the time of progression to accel-
erated or blast phase CML. The National Comprehensive
Cancer Network adopted these guidelines in 2007 (Prac-
tice Guidelines in Oncology: Chronic myelogenous leu-
kemia, http://www.nccn.org/professionals/physician_gls/
PDF/cml.pdf, accessed 9/1/08).
Criteria for inadequate initial response (ie, primary re-
sistance) include lack of complete hematological re-
sponse, minimal cytogenetic response or lack of major
cytogenetic response at 3, 6, and 12 months respectively
and are similar to the criteria adopted by the European
LeukemiaNet.14 Criteria for loss of response to TKI (ie,
secondary resistance) are also based on cytogenetic
and/or hematological relapse, with variable use of molec-
ular relapse criteria. One proposed molecular trigger for
mutation testing is a tenfold or greater increase in BCR-
ABL transcript levels, although smaller rises in BCR-ABL
transcript levels may also be predictive of mutation de-
velopment.15 However, use of increasing BCR-ABL tran-
scripts levels as the sole criterion for triggering a mutation
screen are not yet universally adopted, in part because a
universal standard for normalizing BCR-ABL RQ-PCR is
not yet available making values obtained at different cen-
ters difficult to compare.
There are no widely adopted guidelines as yet for the
use of mutation screening in Ph ALL, although more
intensive screening based solely on RQ-PCR levels may
be warranted. Screening samples for BCR-ABL KD mu-
tations from patients with Ph ALL who have never re-
ceived TKI therapy is not warranted, except perhaps as a
baseline for subsequent TKI treatment.9
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Which Techniques Are Used to Detect
BCR-ABL KD Mutations?
The particular methods used to detect BCR-ABL KD mu-
tations will obviously have a great influence on the de-
tection frequency, analytical sensitivity, and in turn the
clinical impact of such testing (Table 1). The various
mutation detection methods available have widely differ-
ing analytical sensitivities, from the least sensitive direct
Sanger sequencing method, detecting a mutation
present in approximately 1 in 5 BCR-ABL transcripts, to
the highly sensitive mutation-specific quantitative PCR
methods, which can reliably detect a mutant transcript
down to 1 in 10,000 BCR-ABL transcripts. Because the
detection of low levels of mutant clones may not be
clinically significant, direct sequencing of the BCR-ABL
transcript by the Sanger method is currently the most
appropriate screening test, and was recommended by
an international consensus panel.16
Other screening methods for BCR-ABL KD mutations
that have been reported include denaturing high perfor-
mance liquid chromatography (with follow-up definitive
sequencing of abnormal cases), targeted microarrays,
and liquid bead arrays. Several quantitative mutation de-
tection methods that have been developed to track the
level or proportion of a mutated clone after therapy
switch,17 including PCR-based pyrosequencing18 and
mutation-specific quantitative PCR, have been the most
widely adopted but digital PCR applications using mi-
crofluidic separation have also been tried.19 These quan-
titative assays are most clearly relevant for therapy with
novel agents against the pan-resistant T315I mutation,
and several laboratories now offer this testing as a stand-
alone assay. This type of directed approach is not likely
to replace the less sensitive full BCR-ABL KD mutation
screens in the near future.
How Should the Finding of a Particular
BCR-ABL Mutation Be Interpreted?
At least 70 different mutations involving 57 different
amino acids have been reported in the BCR-ABL kinase
domain. However, many of these mutations are quite rare
in imatinib-treated clinical samples, given that 15 amino
acid substitutions account for 80% to 90% of all reported
imatinib-resistant mutations, and 7 mutated codons
(G250, Y253, E255, T315, M351, F359, and H396) ac-
count for a cumulative 60% to 70% (Table 2).16,20–29 The
more common mutations cluster to one of four “hot spots”
within the BCR-ABL KD (Figure 1), namely: 1) the ATP-
binding P-loop (amino acids 248–256); 2) the imatinib
binding region (amino acids 315–317); 3) the catalytic
domain (amino acids 350–363); and 4) the activation
(A)-loop (amino acids 381–402). The A-loop is a major
regulator of BCR-ABL kinase activity by adopting either a
closed (inactive) or open (active) conformation, and A-
loop mutations often destabilize the inactive conformation
that is required for imatinib binding.
Specific mutation types are also becoming closely as-
sociated with newer generation TKIs, with dasatinib use
often selecting for mutations at amino acids 299 (V299L),
315 (T315I), and 317 (F317L/I),6,7,30 and nilotinib prefer-
entially selecting for certain mutations in the P-loop
(G250E, Y253H, E255K), T315I, or F311I.6 The spectrum
of mutations in patients being treated with dasatinib or
nilotinib is closely mimicked by the pattern of clones that
evolve from in vitro exposure of BCR-ABL-expressing cell
lines to these same drugs.
The clinical interpretation and significance of finding a
particular BCR-ABL KD mutation can be complex. The
relative degree of imatinib resistance, defined by in vitro
drug inhibition of kinase activity or growth of mutant-
expressing cell lines, is quite variable for different BCR-
ABL KD mutations, with some mutations conferring only
low-level resistance that may respond to imatinib dose
escalation (eg, M351T), and others conferring high-level
resistance to imatinib and other TKIs (eg, T315I, Y253H,
E255K), thus implying imatinib “failure” and the need for
a change in therapy (Table 2).
The increasing utilization of the second-generation ki-
nase inhibitors, particularly dasatinib and nilotinib, has
further complicated the interpretation of BCR-ABL KD
mutation analyses. It appears that the spectrum of resis-
tance mutations seen following use of these more pow-
erful TKIs are more restricted than those seen following
imatinib treatment, but often have complex dynamics
dependent on the specific treatment regimen and the
prior therapy. Common scenarios include 1) (complete or
Table 1. Comparison of Methods for BCR-ABL Mutation Detection
Method Sensitivity Advantages Disadvantages
Direct sequencing
(Sanger)
20% to 25% Bidirectional confirmation May require nested PCR to obtain enough
product
Routine method available in most labs Expensive and time-consuming
Not quantitative
Pyrosequencing 1% to 5% Lower cost Shorter read lengths require more PCR
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incomplete) clonal replacement of an imatinib-selected
mutation with a completely different dasatinib or nilotinib-
selected clone; 2) new emergence of a BCR-ABL KD
mutation only after exposure to a second-generation
agent (but not with prior imatinib); and 3) persistence of
an imatinib-selected mutation plus the acquisition of an
additional mutation after dasatinib/nilotinib exposure;
sometimes even on the same transcript.6
For most individual BCR-ABL KD mutations, there is
good correlation between demonstration of resistance to
TKIs in vitro and development of resistance in vivo. Many
of the mutations elicited by in vitro treatment with one of
the TKIs have subsequently been identified in patients
with clinical resistance to that TKI.6,7 In addition, there is
good correlation between in vitro sensitivity and clinical
response. For example, the V299L mutation, which is
associated with resistance to dasatinib, remains sensitive
to imatinib in vitro25 and has demonstrated response clin-
ically to imatinib and to the imatinib analog nilotinib.7
However, because there are multiple mechanisms of
resistance to TKIs in CML and ALL, and many different
mutations can emerge during therapy, the identification
of a mutation while on TKI therapy does not necessarily
correlate with clinical resistance.5,31 Although the pres-
ence of a BCR-ABL KD mutation is often only evaluated in
a patient who is failing (or at risk of failing) TKI therapy,
the development of these mutations may not be depen-
dent on the presence of these drugs, but may, instead,
be part of the natural history of the disease.26 In support
of this hypothesis, mutations are more prevalent in pa-
tients with a more advanced disease phase,2,3 and are
still often detectable both in pre-therapeutic samples (by
sensitive allele-specific PCR methods),32,33 and in pa-
tients with a complete cytogenetic response to TKI ther-
apy.11,12 Furthermore, the presence of a mutation per se,
even the highly pan-resistant T315I mutation (at least at a
low clonal burden), may not impart a growth advan-
tage,34 leading to inconsistent association with resis-
tance to therapy.33
How Should BCR-ABL Mutation Studies Be
Reported?
Following the molecular checklist guidelines of the Col-
lege of American Pathologists, we propose that all re-
Table 2. Prevalence and Drug Sensitivity of Common Imatinib-Resistant BCR-ABL Mutations
Amino acid change* Prevalence in imatinib-resistant CML† Imatinib IC50 (nM) Nilotinib IC50 (nM) Dasatinib IC50 (nM)
Wild-type 260 13 0.8
M237I 3% 1550 35 NA
M244V 4% 2000 38 1.3
L248V 2% 2100 100 NA
G250E 5% to 9% 1350 48 1.8
Q252H 2% to 3% 1325 70 3.4
Y253F 6% 3475 125 1.4
Y253H 5% 6400 450 1.3
E255K 9% to 14% 5200 200 5.6
E255V 2% to 3% 6400 430 11
D276G 2% 2500 80 NA
F311L 1% to 2% 480 23 1.3
F311I 1% NA NA NA
F311V 1% 3500 160 NA
T315I 13% to 16% 6400 2000 200
F317L 3% to 4% 1050 50 7.4
M351T 10% to 13% 880 15 1.1
E355G 2% to 3% 2400 47 1.8
F359V 4% to 5% 1825 175 2.2
F359C 1% 2400 290 NA
V379I 1% 1600 51 0.8
L387M 1% NA NA NA
M388L 1% 530 20 NA
H396R 4% 1750 41 1.3
H396P 1% 850 41 0.6
S417Y/T 1% NA NA NA
E450G 1% to 2% NA NA NA
E453K/V/D 1% NA NA NA
E459L/K/G 1% NA NA NA
F486S 2% NA NA NA
*Only the most common BCR-ABL KD mutations in imatinib-resistant patients are listed. The positions are those of the GenBank sequence
(accession number AAB60394).
†Mutation prevalence data represent the percentage of a particular mutation relative to all mutated cases and are from references 20 and 16.
In vitro TKI sensitivity was determined in proliferation assays of cells transfected with each BCR-ABL variant as per reference 21, with “high” sensitivity
defined as an IC50 of 1000 nM imatinib, 50 nM nilotinib, and 3 nM dasatinib. “Low” sensitivity was defined as an IC50 of 3000 nM imatinib, 500 nM
nilotinib, and 60 nM dasatinib. “Intermediate” sensitivity would be defined as an IC50 value in between the “high” and “low” cutoffs.
Achievable plasma trough levels are approximately (depending on dose) 1500 nM for imatinib,22 2000 nM for nilotinib,23 and 100 nM for dasatinib.24
The IC50 values for each drug for in vitro inhibition of proliferation of particular BCR-ABL mutants are somewhat variable depending on the study and the
assay method.21,24–28 The IC50 values in the table are from reference,
21 except for mutants M237I, L248V, D276G, F311V, F359C, and M388L, which
are from reference 28.28 The IC50 values for mutant E355G are from reference 29 for imatinib and dasatinib, and from reference 28 for nilotinib.
28,29
NA, IC50 values not available.
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ports on BCR-ABL mutational analysis should include
pre- and post-analytical elements, in addition to the as-
say result, as summarized in Table 3. Methodology
should be briefly summarized including the region of the
BCR-ABL KD that was evaluated and the nominal analytic
sensitivity of the assay, defined as the lowest fraction of
BCR-ABL transcripts with a mutation that can be reliably
detected. The report should also include a statement that
BCR-ABL KD mutation analysis does not always provide
a full explanation for apparent resistance to TKI therapy.
If a mutation is detected, this should be indicated
according to standard amino acid substitution nomencla-
ture.35 If a non-quantitative mutation detection method
such as Sanger sequencing is used, an estimate of the
relative quantity of the mutation can also be provided (eg,
only mutated sequence, mixed mutated/unmutated se-
quences or low level mutation detected). If more than one
mutation is identified, this type of semiquantitative esti-
mate is important to compare the relative shifts seen in
follow-up samples. If novel mutations or other genetic
findings (eg, insertion/deletion events, known or previ-
ously unreported single nucleotide polymorphisms) are
identified, a statement should be added indicating that
the impact of the alteration on TKI resistance is not cur-
rently known.
A brief interpretation could also be included to state if
the detected mutation(s) has been associated with in vitro
or in vivo TKI, with an appropriate citation such as refer-
ences 16 and 36. Other information that could be in-
cluded in a report concern the clinical indications for
testing (eg, loss of BCR-ABL molecular response, cyto-
genetic relapse, etc), the current TKI therapy, and the
most recent BCR-ABL transcript level. Although the ulti-
mate goal of mutation testing is to guide therapeutic
decisions, the report should not contain specific recom-
mendations concerning which therapies are optimal for
any given patient.
What Are the Needs for Standardization and
Proficiency Testing?
As described above, direct sequencing of the BCR-ABL
transcript is the predominant method for BCR-ABL KD
mutation detection in the clinical setting, however a range
of other qualitative and quantitative methods are now
available. This proliferation of methodologies raises the
urgent but as yet unmet need for standards, calibrators,
and proficiency testing programs, as required for all clin-
ical laboratories that are accredited through Clinical Lab-
oratory Improvement Amendments and/or the College of
American Pathologists mechanisms.
Several studies have raised a number of problematic
quality control issues for BCR-ABL transcript and muta-
tion tests that should be considered in future efforts.16,37
The most important pre-analytical consideration is the
quality of the extracted RNA. Many laboratories use
blood collected in EDTA tubes where RNA quality may be
compromised, compared with RNA-stabilizing tubes.
This is an important consideration if there is a long delay
between acquiring the specimen and RNA preparation.
Figure 1. Schematic of the BCR-ABL fusion tran-
script and the location of reported KD mutations
and alternate transcripts. Common areas for lo-
cation of BCR (blue box) and ABL1 (yellow box
including KD) primers for nested PCR (blue
arrows) and BCR-ABL KD PCR (red arrows)
used for direct sequencing assays are indicated.
Colored triangles indicate the location of KD
mutations reported in TKI-resistant samples
(black for imatinib, green for nilotinib/imatinib,
blue for dasatinib/imatinib, and red for all three
TKIs). The KD subdomains, exons, and amino
acid numbers are shown. P-loop: phosphate
binding loop; IM binding site: imatinib binding
region; C-loop: kinase catalytic domain; and A-
loop: activation loop. The locations of four de-
letions in the BCR-ABL transcript that were most
commonly reported in our laboratory survey are
included in the lower part of the figure.
Table 3. Reporting Recommendations for BCR-ABL KD
Mutational Analysis
Pre-analytic
Clinical indication (including current and/or past TKI
therapy, if available)
Tissue source (e.g. peripheral blood, bone marrow
aspirate)
Most recent BCR-ABL RQ-PCR results or trend data (if
available)
Analytic
Methods description including region that is
sequenced, with assay sensitivity and controls
BCR-ABL amplification and control results
(acceptable/fail)
Mutation not detected
Mutation detected: amino acid change (e.g., T315I),
and relative abundance of mutation (e.g., mixed
mutated/unmutated) [inclusion of nucleotide change
is optional]
Other sequence alterations (e.g., ins/del, known SNP)
Post-analytic
Comment if mutation is known to confer clinical and/or
in vitro resistance to a particular TKI, with
appropriate reference
Comment if novel mutation(s) identified and denote
lack of published clinical or laboratory data
concerning its TKI resistance profile
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Depending on the extraction method used, RNA quality
can vary significantly. Therefore, as a pre-analytical con-
trol, many laboratories establish a cutoff for the minimum
level of control gene amplification required before report-
ing RQ-PCR assays for BCR-ABL level or mutation status.
In the analytic phase of BCR-ABL testing, it has been
shown that cDNA synthesis (reverse transcription) is the
most important cause of assay variation.16 Additionally in
those laboratories that use a nested PCR strategy to
amplify the BCR-ABL transcript before sequencing to
avoid amplifying the non-translocated ABL1 transcript,
variations in the efficiency of the two PCR steps can
dramatically influence BCR-ABL KD mutation detection.
A common issue for proficiency testing in the molecu-
lar pathology arena is the lack of standardization of re-
agents and technology platforms. A typical scenario in
molecular pathology testing begins with individual labo-
ratories independently developing testing strategies, fol-
lowed by industry development of analyte-specific re-
agents and, eventually and only in a minority of cases,
kits approved by the Food and Drug Administration for
clinical use. In the initial phase, each laboratory’s assay is
different, often with unknown strengths and weaknesses.
Currently, as with BCR-ABL RQ-PCR assays, there is a
need for reference material that can be used to assess
the sensitivity, dynamic range and normalized values for
each assay.37
As standards for quantitative BCR-ABL RQ-PCR test-
ing are made available, the goal should be to include
levels of BCR-ABL transcript normalized to the interna-
tional major molecular response scale as a criteria for
triggering BCR-ABL KD mutation testing.13,16
What Alterations in BCR-ABL Have Been
Reported in Resistant Samples besides Point
Mutations?
A number of laboratories that routinely sequence the
BCR-ABL transcript have found that point mutations are
not the only frequently seen genetic alteration. In our
survey of clinical laboratories performing BCR-ABL mu-
tation screening, 7 of 12 (58%) observed alternate splic-
ing, insertions, deletions and/or duplications. A 35-bp
intronic insertion, which occurred at the exon 8/9 junction
after amino acid 474, was the most commonly reported,
seen by five laboratories at a frequency of 2% to 10%, but
was also seen by two laboratories in the ABL1 transcript
in BCR-ABL negative samples. Translation of this mutant
would produce a BCR-ABL protein with an insertion of 10
amino acids followed by a stop codon.38,39 Alternatively
spliced products with loss of entire exons 4, 7, and 8
were reported by five laboratories. Deletions described
in a clinical laboratory survey (see below) included
Leu248_Cys475del (found by three laboratories with fre-
quency of 2%), Arg326fs reported by two laboratories,
and Leu248_Lys274del, Met318_Thr319delinsLeu, and
Ser385_Leu445del reported by one laboratory each.
The significance of such grossly altered transcripts is
unclear, but many would be predicted to lack active
BCR-ABL kinase activity. A recent publication suggests
that such deletions and proteins arising from alternatively
spliced transcripts may act as dominant-negative inhibi-
tors of the full-length BCR-ABL.40
What Is the State of Current Practice in Clinical
Laboratories for BCR-ABL KD Mutation
Testing?
To assess how the current state of clinical testing con-
forms to recommended practice, we conducted a survey
of American and Canadian accredited clinical laborato-
ries performing routine BCR-ABL KD mutational analysis.
Fourteen laboratories responded and all performed test-
ing on RNA extracted from blood or bone marrow aspi-
rate material followed by cDNA conversion before muta-
tion detection. Direct Sanger sequencing using Applied
Biosystems BigDye Terminator chemistry on the ABI
3100, 3130, or 3730 genetic analyzers was used in 11/14
(79%) labs with most using a nested approach with BCR-
ABL PCR amplification followed by ABL KD PCR ampli-
fication in a second round; pyrosequencing (directed
against codon 315) was used in two laboratories (includ-
ing one also using Sanger sequencing), and microarray
or liquid-bead array approaches for specific mutation
panels were used in one laboratory each. Quantification
of the T315I mutation was available in three laboratories.
The reported turn-around times for reporting the test re-
sults were less than 7 days (23%), 8 to 13 days (46%), or
14 to 28 days (23%). Nine of 14 (64%) laboratories had
no preference with regards to sample type; RNA was
extracted from bone marrow or peripheral blood.
The majority of laboratories (11/13, 85%) reported
screening the entire KD (ABL1 exons 4 to 9, see sche-
matic in Figure 1) for mutations, while two laboratories
only tested for a specific panel of known mutations. Most
labs performed bidirectional sequencing and reported
positive results only when detecting a mutation in both
forward- and reverse-strand chromatograms, with a com-
monly reported sensitivity of 10% to 20%. All clinical
laboratories surveyed currently report only BCR-ABL KD
point mutations producing amino acid shifts. Only a mi-
nority of laboratories reported whether the mutation was
previously reported to confer resistance to kinase inhib-
itors, either based on clinical experience or based on
data from in vitro screens. Most laboratories, while ob-
serving alternate splice products and insertion/deletions
(see previous section), synonymous mutations or single
nucleotide polymorphisms, do not include this finding on
their reports because of limited information regarding
their clinical significance.
What are the Future Directions in BCR-ABL
Mutation Reporting?
There is a clear need for progress in implementing stan-
dards for reporting the results of BCR-ABL mutation stud-
ies, and (as demonstrated by our survey) also a need for
tools to aid in the clinical interpretation of these results.
As the number of known BCR-ABL KD mutations in-
BCR-ABL Mutation Guidelines 9
JMD January 2009, Vol. 11, No. 1
crease, and the number of TKIs increase, there is a
greater need for a publicly-available comprehensive da-
tabase to serve as a reference for interpreting the clinical
significance of the results of mutation screens, as has
been done in infectious diseases (HIV Drug Resistance
Database, http://hivdb.stanford.edu, accessed 9/1/08)
and genetic syndromes (Human Gene Mutation Data-
base, http://www.hgmd.cf.ac.uk/ac, accessed 9/1/08).
Such a database would be invaluable in differentiating
benign polymorphisms/passenger mutations from resis-
tance mutations and assisting in predicting response to a
different TKI to help in selecting an alternate therapy.
Such a database should present information on the in
vivo context in which specific mutations have previously
developed (eg, which resistance mutation are found in
patients relapsing after treatment with dasatinib or nilo-
tinib)6,7 but also summarize the in vitro sensitivity of par-
ticular mutations to each TKI (Table 2).21 There is an
increasingly large amount of published data on the ef-
fects of particular TKIs on inhibiting KD-mutated BCR-
ABL in kinase assays, on inhibiting growth of cell lines
expressing particular KD-mutated BCR-ABL proteins, or
in promoting outgrowth of certain mutations in long-term
in vitro culture (mutagenesis screens).24 All of these data
elements provide corroborating evidence of the pattern
of drug resistance for each particular mutation under
controlled conditions. The type of database we outline
would provide easy access to a set of laboratory infor-
mation needed for clinical decision making. To be truly
useful the database would need to be updated frequently
with new information and be carefully curated for ac-
curacy. It would also need to be free of commercial
influences.
In silico modeling of the effect of a mutation on kinase
function based on structural protein data (including co-
crystallization of the ABL kinase domain with specific
TKIs) can also predict which inhibitors will be effective
against which BCR-ABL KD mutations in vivo.18,41 This
approach has elucidated the mechanism of resistance
for the BCR-ABL pan-resistant mutation T315I, which is a
key contact residue for TKIs,41 and of imatinib-resistance
mutations that destabilize the inactive conformation of
BCR-ABL.
Summary
Given our evolving understanding of the molecular
events mediating resistance in CML and Ph ALL, stan-
dards for reporting of BCR-ABL mutational studies would
benefit from a greater degree of uniformity. Commercial-
ly-available reference samples and calibrators as well as
a publicly available BCR-ABL mutation database are the
currently needed resources to allow laboratories and cli-
nicians to interpret the significance of BCR-ABL KD mu-
tation studies. While these standardization efforts are
proceeding, mutation studies should be based on the
already developed criteria for clinical resistance (summa-
rized above) to better ensure appropriate utilization. As
shared databases become more widely available, the
most appropriate statements regarding the clinical sig-
nificance of specific mutations will be better defined and
allow more precise guidance to be given.
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